Table 2: Baseline disease characteristics of patients with AS and PsA.

Characteristics AS (N = 187) PsA (N = 385) P-value Total (N = 572)
Disease activity at baseline, mean (SD)
      PhGA, score 0-10 5.9 (1.8) 5.5 (2.1) 0.051°°° 5.6 (2.0)
      BASDAI, score 0-10 5.5 (1.9) NA 0.384°°° 5.5 (1.9)
      PASI, score NA 8.8 (12.4) NA 8.8 (12.4)
      Tender joints (68 joints) NA 7.9 (8.1) NA 7.9 (8.1)
      Swollen joints (66 joints) NA 4.1 (5.5) NA 4.1 (5.5)
      BDI-II, 0–63 12.7 (9.2) 11.5 (9.2) 0.127°°° 11.9 (9.2)
      PsAID-12, 0–10 NA 5.0 (2.2) NA 5.0 (2.2)
      ASAS-HI, 0–17 8.4 (3.7) NA NA 8.4 (3.7)
      CRP (mg/L), median 7.6 4.6 0.003°°° 5.5
      CRP (mg/L) IQR (Q1-Q3) 3.0-22.0 2.2-11.8 NA 2.4-13.5
      CRP >5.0 mg/L, n (%) 94 (50.3) 148 (38.4) 0.004° 242 (42.3)
Comorbidities at baseline, n (%)
Coronary heart disease 5 (2.7) 32 (8.3) 0.065°° 37 (6.5)
Stroke 0 8 (2.1) 0.134°° 8 (1.4)
Heart failure 1 (0.5) 12 (3.1) 0.202°° 13 (2.3)
Plaque psoriasis
      Mild 11 (5.9) 81 (21.1) NA 92 (16.1)
      Moderate 6 (3.2) 111 (28.9) NA 117 (20.5)
      Severe 1 (0.5) 48 (12.5) NA 49 (8.6)
Uveitis 9 (4.8) 3 (0.8) 0.005°° 12 (2.1)
Depression* 17 (9.1) 60 (15.6) 0.021°° 77 (13.5)

*Only in case of diagnosis by physician/reported in patient health record.
Missing values not included in the % calculation for PsA subgroup.
ACR, American College of Rheumatology; AS, ankylosing spondylitis; ASAS-HI, Assessment of SpondyloArthritis international Society Health Index; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BDI-II, Beck Depression Inventory; CHD, Coronary heart disease; CRP, C-Reactive Protein; IQR, interquartile range; N, number of patients; NA, Not Applicable/Not Available; PASI, Psoriasis Area and Severity Index; PhGA, Physician’s Global Assessment; PsA, psoriatic arthritis; PsAID-12, Psoriasis Arthritis Impact of Disease (12-item); SD, standard deviation.
°Fisher´s exact test, °°Chi-square test, °°°Wilcoxon test